Perspective Therapeutics Inc. (CATX) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Perspective Therapeutics Inc. (CATX:NYSE), powered by AI.

Current Price
$2.93
P/E Ratio
-2.1
Market Cap
216M
Sector
Healthcare
What is the Perspective Therapeutics Inc. stock price forecast?

Perspective Therapeutics Inc. is currently trading at $2.93. View real-time AI analysis on Alpha Lenz.

What is Perspective Therapeutics Inc. insider trading activity?

View the latest insider trading data for Perspective Therapeutics Inc. on Alpha Lenz.

What is Perspective Therapeutics Inc.'s P/E ratio?

Perspective Therapeutics Inc.'s P/E ratio is -2.1.

Perspective Therapeutics Inc.

NYSE · CATX
$2.93-0.01(-0.34%)Pre-marketNYSE regular session 09:30–16:00 ET
Ask about Perspective Therapeutics Inc.'s future dividend policy...
Alpha Chat Insight

Perspective Therapeutics Inc. trades at a P/E of -2.1 (undervalued) with modest ROE of -41.4%.

Ask for details

Company Overview

Perspective Therapeutics Inc. is a biotechnology company focused on the discovery, development, and commercialization of innovative therapeutics and technologies to treat various diseases, primarily within the oncology sector. Its primary function is to advance research that can lead to practical cancer treatment solutions, potentially impacting patient care significantly. The company engages in developing novel targeted therapies, often collaborating with leading research institutions and utilizing cutting-edge scientific techniques. Perspective Therapeutics Inc. plays a critical role in the healthcare market by addressing unmet medical needs and contributing to the growing demand for personalized medicine approaches. The work undertaken by the company holds substantial importance for the biotech and pharmaceutical industries as it seeks to improve therapeutic outcomes and enhance medical capabilities in combating cancer and other serious illnesses. The company's initiatives not only underscore the importance of biotechnology in advancing healthcare solutions but also highlight the ongoing evolution within the medical research landscape.

CEOMr. Johan M. Spoor
SectorHealthcare
IndustryMedical Devices
Employees138

Company Statistics

FY 2025

Profile

$216.27MMarket Cap
$0.00Revenue
0.00Shares Out
138Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

-2.10P/E
1.04P/B
N/AEV/Sales
-1.87EV/EBITDA
-2.27P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-33.92%ROA
-41.44%ROE
-34.22%ROIC

Financial Health

$30.63MCash & Cash Equivalents
$29.31MNet Debt
28.95%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Perspective Therapeutics Inc. (ticker: CATX) is a company listed on NYSE in the Healthcare sector (Medical Devices). It has approximately 138 employees. Market cap is $216M.

The current price is $2.93 with a P/E ratio of -2.1x and P/B of 1.04x.

ROE is -41.44%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Perspective Therapeutics Inc. (CATX) Stock Forecast 2026 $2.93 — Price, Financials & Analyst Targets | Alpha Lenz